Bioengineered Nanomedicines Targeting the Intestinal FC Receptor Achieve the Improved Glucoregulatory Effect of Semaglutide in a Type 2 Diabetic Mice Model

Neonatal Fc receptor-targeted nanoparticles were designed to enhance the oral delivery of semaglutide, and proved to be an effective platform for improving the pharmacological effect of semaglutide in a type 2 diabetes mellitus-induced mice model.